TSNDFTerrAscend Corp.
The schedule
- Thu15Oct
Into late 2026, any credible movement on U.S. federal cannabis policy under President Trump—such as progress on banking reform or rescheduling—could act as a sector-wide rerating catalyst; for TerrAscend, constructive signals from a base near $0.90 could drive a squeeze toward $1.40, while continued inaction or tougher enforcement rhetoric would keep capital constrained and likely pull the stock back toward $1.40.
- Sun1Nov
By late 2026, TerrAscend may need to address its roughly $256 million in debt through refinancing or equity-linked financing; if management can extend maturities on reasonable terms without heavy dilution, the stock around $0.85 could grind up toward $1.05, but a dilutive raise or expensive refinancing could drive a repricing down toward $1.05.
- Mon24May
Q3 2026 earnings around a base of $0.40, alongside an early view of 2027 strategy, will help investors judge whether TerrAscend has turned the corner on revenue declines while maintaining positive free cash flow; clear evidence of stable volumes, disciplined capex, and a credible path to de-levering could support a move toward $1.20, while any relapse into losses or weaker guidance would likely re-anchor the stock closer to $0.50.
- Mon30Aug
Past
- Thu13Aug
Actual outcome: Mixed
TerrAscend reported Q2 2026 EPS of $0.0082, exactly matching consensus estimates. With earnings coming in line and no major surprises regarding free cash flow generation or debt reduction, the stock remained flat as investors lacked a clear directional catalyst to drive shares toward either the bull or bear targets.
Q2 2026 results around a base price of $0.75 will be scrutinized for free-cash-flow durability and debt reduction; confirmation that TerrAscend can consistently produce positive FCF and begin to de-lever could justify a move toward $1.15, while renewed cash burn or rising leverage fears would likely pressure the stock toward $1.15.
- Wed1Jul
Actual outcome: Bear
Despite positive corporate developments—including the acquisition of a high-performing New Jersey dispensary, a $21.7 million debt financing to retire higher-interest debt, and filing a proxy statement for a potential U.S. exchange uplisting—the stock declined 6.6% over the period. The market's focus likely remained on broader state-level pricing compression and regulatory uncertainties in key markets, which overshadowed the company's strategic expansion and balance sheet improvements.
Through mid-summer, evolving state-level rules and competitive dynamics in core markets such as New Jersey, Pennsylvania, and Michigan will shape TerrAscend’s pricing power; if regulatory changes remain manageable and wholesale pricing stabilizes, the stock could trade up toward $1.05 from $0.80, but renewed price compression or tougher compliance rules could drag it down toward $1.05.
- Thu7May
Actual outcome: Bear · $0.68 at outcome
TerrAscend reported Q1 2026 net revenue of $65.5 million and met EPS estimates of $0.0082, while maintaining a gross profit margin of 52.8% and generating $7.8 million in free cash flow. Despite the continued profitability and cost controls, the top-line revenue figure fell short of expectations for stabilization, prompting an 8.2% decline in the stock as investors remained concerned about ongoing sales pressure.
Q1 2026 earnings around $0.81 will be key for showing that TerrAscend’s revenue declines are stabilizing and that cost controls can sustain the recent move back to profitability; a clean print with reaffirmed or improved outlook could support a move toward $1.10, while another step-down in sales or margins would likely push the stock back toward $1.10.
